Design, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles - A new family of high affinity CB1 cannabinoid ligands

Molecules

Volumn 18, Issue 4, 2013, Pages 3972-4001

  Mella Raipán, Jaime A ^a   Lagos, Carlos F ^b   Recabarren Gajardo, Gonzalo ^b   Espinosa Bustos, Christian ^b   Romero Parra, Javier ^b   Pessoa Mahana, Hernán ^c   Iturriaga Vásquez, Patricio ^c   Pessoa Mahana, Carlos David ^b  

^a UNIVERSIDAD DE VALPARAÍSO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

3D QSAR; Binding; Cannabinoid; CB1 receptor; Docking

Indexed keywords

2 (2' PYRIDYL)BENZIMIDAZOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 2-(2'-PYRIDYL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; LIGAND; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; METABOLISM; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BENZIMIDAZOLES; BENZOXAZINES; CANNABINOIDS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MORPHOLINES; NAPHTHALENES; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, CANNABINOID, CB1;

EID: 84876762080     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18043972     Document Type: Article

References (44)

1. Diaz, P.; Xu, J.; Astruc-Diaz, F.; Pan, H.M.; Brown, D.L.; Naguib, M. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J. Med. Chem. 2008, 51, 4932-4947.
2. Lozano-Ondoua, A.N.; Wright, C.; Vardanyan, A.; King, T.; Largent-Milnes, T.M.; Nelson, M.; Jimenez-Andrade, J.M.; Mantyh, P.W.; Vanderah, T.W. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci. 2010, 86, 646-653.
3. Sharkey, K.A.; Cristino, L.; Oland, L.D.; van Sickle, M.D.; Starowicz, K.; Pittman, Q.J.; Guglielmotti, V.; Davison, J.S.; di Marzo, V. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 2007, 25, 2773-2782.
4. Tam, J.; Cinar, R.; Liu, J.; Godlewski, G.; Wesley, D.; Jourdan, T.; Szanda, G.; Mukhopadhyay, B.; Chedester, L.; Liow, J.S.; et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012, 16, 167-179.
5. Yan, L.; Huo, P.; Debenham, J.S.; Madsen-Duggan, C.B.; Lao, J.; Chen, R.Z.; Xiao, J.C.; Shen, C.P.; Stribling, D.S.; Shearman, L.P.; et al. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4- dichlorophenyl)-2,2-dimethyl-3,4-dihydro- 2H-pyr ano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole- 3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. J. Med. Chem. 2010, 53, 4028-4037.
6. Di Marzo, V.; Bifulco, M.; de Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004, 3, 771-784.
7. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462.
8. Devane, W.A.; Dysarz, F.A., 3rd; Johnson, M.R.; Melvin, L.S.; Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34, 605-613.
9. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
10. Padgett, L.W. Recent developments in cannabinoid ligands. Life Sci. 2005, 77, 1767-1798.
11. Thakur, G.A.; Nikas, S.P.; Duclos, R.I., Jr.; Makriyannis, A. Methods for the synthesis of cannabinergic ligands. Methods Mol. Med. 2006, 123, 113-148.
12. Palmer, S.L.; Thakur, G.A.; Makriyannis, A. Cannabinergic ligands. Chem. Phys. Lipids 2002, 121, 3-19.
13. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 1997, 74, 129-180.
14. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 1999, 6, 635-664.
15. Compton, D.R.; Gold, L.H.; Ward, S.J.; Balster, R.L.; Martin, B.R. Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1992, 263, 1118-1126.
16. Makriyannis, A.; Deng, H. Cannabimimetic indole derivatives. WO200128557, 26 April 2001.
17. Huffman, J.W.; Dai, D.; Martin, B.R.; Compton, D.R. Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorg. Med. Chem. Lett. 1994, 4, 563-566.
18. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 1998, 284, 291-297.
19. Rohde, J.; Kim, C.; Nakai, T. Cannabinoid receptor agonist. WO2011100324, 18 August 2011.
20. Watson, C.; Owen, D.R.; Harding, D.; Kon-I, K.; Lewis, M.L.; Mason, H.J.; Matsumizu, M.; Mukaiyama, T.; Rodriguez-Lens, M.; Shima, A.; et al. Optimisation of a novel series of selective CNS penetrant CB2 agonists. Bioorg. Med. Chem. Lett. 2011, 21, 4284-4287.
21. Blaazer, A.R.; Lange, J.H.M.; van der Neut, M.A.W.; Mulder, A.; den Boon, F.S.; Werkman, T.R.; Kruse, C.G.; Wadman, W.J. Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure-activity relationships, physicochemical properties and biological activity. Eu. J. Med. Chem. 2011, 46, 5086-5098.
22. Trotter, B.W.; Nanda, K.K.; Burgey, C.S.; Potteiger, C.M.; Deng, J.Z.; Green, A.I.; Hartnett, J.C.; Kett, N.R.; Wu, Z.; Henze, D.A.; et al. Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy. Bioorg. Med. Chem. Lett. 2011, 21, 2354-2358.
23. Araya, K.A.; David Pessoa Mahana, C.; Gonzalez, L.G. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC. Eur. J. Pharmacol. 2007, 572, 32-39.
24. Gonzalez, A.; Duran, L.S.; Araya-Secchi, R.; Garate, J.A.; Pessoa-Mahana, C.D.; Lagos, C.F.; Perez-Acle, T. Computational modeling study of functional microdomains in cannabinoid receptor type 1. Bioorg. Med. Chem. 2008, 16, 4378-4389.
25. Bahrami, K.; Khodaei, M.M.; Naali, F. Mild and highly efficient method for the synthesis of 2-arylbenzimidazoles and 2-arylbenzothiazoles. J. Org. Chem. 2008, 73, 6835-6837.
26. Vásquez, D.; Lagos, C.F.; Mella-Raipán, J.; Gonzalez, L.; Ebensperger, R.; Alvarez-Figueroa, M.J.; Pessoa-Mahana, C.D. 1-benzoyl-2-(2-nitrophenyl)-1H-benzimidazole derivatives: A novel approach to the development of new HIV-1 reverse transcriptase inhibitors. J. Chil. Chem. Soc. 2007, 52, 1281-1287.
27. Pessoa-Mahana, C.D.; Nuñez, A.; Espinosa, C.; Mella-Raipán, J.; Pessoa-Mahana, H. Synthesis of a novel series of 4-arylpiperazinyl derivatives linked toa 2-(pyridin-3-yl)-1H-benzimidazole as new delavirdine analogues. J. Braz. Chem. Soc. 2010, 21, 63-48.
28. Gonzalez, A.; Murcia, M.; Benhamu, B.; Campillo, M.; Lopez-Rodriguez, M.; Pardo, L. The importance of solvation in the design of ligands targeting membrane proteins. Med. Chem. Commun. 2011, 2, 160-164.
29. Liao, S.Y.; Quian, L.; Lu, H.L.; Shen, Y.; Zheng, K.C. A Combined 2D- and 3D-QSAR Study on Analogues of ARC-111 with Antitumor Activity. QSAR Comb. Sci. 2008, 6, 740-749.
30. Cho, S.J.; Tropsha, A. Cross-validated R2-guided region selection for comparative molecular field analysis: A simple method to achieve consistent results. J. Med. Chem. 1995, 38, 1060-1066.
31. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity - A. Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
32. Gasteiger, J.; Marsili, M. A New Model for Calculating Atomic Charges in Molecules. Tetrahedron Lett. 1980, 19, 3181-3184.
33. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model 2002, 20, 269-276.
34. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
35. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211-1217.
36. Sali, A. Comparative protein modeling by satisfaction of spatial restraints. Mol. Med. Today 1995, 1, 270-277.
37. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995, 23, 318-326.
38. Ballesteros, J.A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing ofstructure-function relations in G protein-coupled receptors. Methods Neurosci. 1995, 25, 366-428.
39. Ramachandran, G.N.; Ramakrishnan, C.; Sasisekharan, V. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 1963, 7, 95-99.
40. Feig, M.; Onufriev, A.; Lee, M.S.; Im, W.; Case, D.A.; Brooks, C.L., 3rd. Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J. Comput. Chem. 2004, 25, 265-284.
41. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
42. Clark, M.; Cramer, R.; Opdenbosch, N.V. Validation of the general purpose Tripos 5.2 force field. J. Comp. Chem. 1989, 10, 982-1012.
43. Oprea, T.I.; Waller, C.L.; Marshall, G.R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem. 1994, 37, 2206-2215.
44. Waller, C.L.; Oprea, T.I.; Giolitti, A.; Marshall, G.R. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentallydetermined alignment rules. J. Med. Chem. 1993, 36, 4152-4160.